[Clinical research activity of the French cancer cooperative network: Overview and perspectives].
Autor: | Dubois C; Groupes coopérateurs en oncologie (GCO), 10, rue de la Grange-Batelière, 75009 Paris, France; Intergroupe francophone en cancérologie thoracique (IFCT), 10, rue de la Grange-Batelière, 75009 Paris, France. Electronic address: claire.dubois@ifct.fr., Morin F; Groupes coopérateurs en oncologie (GCO), 10, rue de la Grange-Batelière, 75009 Paris, France; Intergroupe francophone en cancérologie thoracique (IFCT), 10, rue de la Grange-Batelière, 75009 Paris, France., Moro-Sibilot D; Intergroupe francophone en cancérologie thoracique (IFCT), 10, rue de la Grange-Batelière, 75009 Paris, France., Langlais A; Intergroupe francophone en cancérologie thoracique (IFCT), 10, rue de la Grange-Batelière, 75009 Paris, France., Seitz JF; Fédération francophone de cancérologie digestive (FFCD), 7, boulevard Jeanne-d'Arc, 21000 Dijon, France., Girault C; Fédération francophone de cancérologie digestive (FFCD), 7, boulevard Jeanne-d'Arc, 21000 Dijon, France., Salles G; Centre hospitalier Lyon sud, service d'hématologie, bâtiment 1F, 69495 Pierre-Bénite, France., Haioun C; Centre hospitalier Lyon sud, service d'hématologie, bâtiment 1F, 69495 Pierre-Bénite, France., Deschaseaux P; The lymphoma academic research organisation (LYSARC), centre hospitalier Lyon sud, secteur Sainte-Eugénie, pavillon 6E, 69495 Pierre-Bénite, France., Casassus P; Intergroupe francophone du myélome (IFM), 8, rue de Parme, 75009 Paris, France., Mathiot C; Intergroupe francophone du myélome (IFM), 8, rue de Parme, 75009 Paris, France., Pujade-Lauraine É; Association de recherche sur les cancers dont gynécologiques-groupe d'investigateurs nationaux dans les études des cancers de l'ovaire et du sein (ARCAGY-GINECO), hôpital Hôtel-Dieu, B2, 5(e) étage, 1, parvis Notre-Dame, place Jean-Paul II, 75004 Paris, France., Votan B; Association de recherche sur les cancers dont gynécologiques-groupe d'investigateurs nationaux dans les études des cancers de l'ovaire et du sein (ARCAGY-GINECO), hôpital Hôtel-Dieu, B2, 5(e) étage, 1, parvis Notre-Dame, place Jean-Paul II, 75004 Paris, France., Louvet C; Groupe cooperateur multidisciplinaire en oncologie (GERCOR), 151, rue du Faubourg-Saint-Antoine, 75011 Paris, France., Delpeut C; Groupe cooperateur multidisciplinaire en oncologie (GERCOR), 151, rue du Faubourg-Saint-Antoine, 75011 Paris, France., Bardet É; CHU de Bretonneau, Groupe d'oncologie radiothérapie tête et cou (GORTEC), 2, boulevard Tonnellé, 33044 Tours, France., Vintonenko N; CHU de Bretonneau, Groupe d'oncologie radiothérapie tête et cou (GORTEC), 2, boulevard Tonnellé, 33044 Tours, France., Hoang Xuan K; Intergroupe coopérateur de neuro-oncologie-association des neuro-oncologues d'expression française (IGCNO-ANOCEF), 27, rue du Desous-des-Berges, 75013 Paris, France., Vo M; Intergroupe coopérateur de neuro-oncologie-association des neuro-oncologues d'expression française (IGCNO-ANOCEF), 27, rue du Desous-des-Berges, 75013 Paris, France., Michon J; Société française de lutte contre les cancers et les leucémies de l'enfant et de l'adolescent (SFCE), hôpital Trousseau, Sce d'anatomie et cytologie pathologique, 26, rue du Dr-Netter, 75012 Paris, France., Milleron B; Groupes coopérateurs en oncologie (GCO), 10, rue de la Grange-Batelière, 75009 Paris, France; Intergroupe francophone en cancérologie thoracique (IFCT), 10, rue de la Grange-Batelière, 75009 Paris, France. |
---|---|
Jazyk: | francouzština |
Zdroj: | Bulletin du cancer [Bull Cancer] 2017 Jul - Aug; Vol. 104 (7-8), pp. 652-661. Date of Electronic Publication: 2017 Jul 05. |
DOI: | 10.1016/j.bulcan.2017.05.006 |
Abstrakt: | Introduction: The French Cancer Plan 2014-2019 stresses the importance of strengthening collaboration between all stakeholders involved in the fight against cancer, including cancer cooperative groups and intergroups. This survey aimed to describe the basics characteristics and clinical research activity among the Cancer Cooperative Groups (Groupes coopérateurs en oncologie). The second objective was to identify facilitators and barriers to their research activity. Methods: A questionnaire was sent to all the clinicians involved in 2014 as investigators in a clinical trial sponsored by one of the ten members of the Cancer Cooperative Groups network. The questions were related to their profile, research activity and the infrastructure existing within their healthcare center to support clinical research and related compliance activities. Results: In total, 366 investigators responded to our survey. The academic clinical trials sponsored by the Cancer Cooperative Groups represented an important part of the research activity of the investigators in France in 2014. These academic groups contributed to the opening of many research sites throughout all regions in France. Factors associated with a higher participation of investigators (more than 10 patients enrolled in a trial over a year) include the existing support of healthcare professionals (more than 2 clinical research associate (CRA) OR=11.16 [3.82-32.6] compared to none) and the practice of their research activity in a University Hospital Center (CHU) rather than a Hospital Center (CH) (OR=2.15 [1.20-3.83]). Conclusion: This study highlighted factors that can strengthen investigator clinical research activities and subsequently improve patient access to evidence-based new cancer therapies in France. (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |